Robert Fried

But as a secondary outcome in all three of those studies, we looked at the traditional Parkinson's markers, things like blood flow or motor behavior, and all have shown a significant improvement.

So we're very encouraged, and we've just completed a four-year study with 400 participants of Parkinson's, 200 received a placebo, 200 received a gram a day of Niagen, every day for a year.

So we're extremely excited.

That's considered a phase three, maybe even a phase four clinical study.

We don't know the results yet.

They haven't been presented to us.

I think at the time that we started that study, a gram a day seemed like a lot.

Today it doesn't seem like a lot.

We all take a gram a day routinely, but back then people were taking two.

We didn't know.

We've learned a lot about its safety.

Maybe if we were to start it today, we'd do a much higher dose, something probably more like three grams, which was that phase two clinical that I mentioned.

But we're particularly intrigued about Parkinson's because it's mitochondrial.

And we know that when you elevate NAD, you have higher functioning mitochondria.

So we're cautiously optimistic.

That's awesome.

Yeah.

I mean, my mom had a Parkinsonian condition.

And I know that there are precious few therapies that actually work, let alone have a condition.

a clinically meaningful disease-modifying effect.